Categories: Business

Novartis to acquire Avidity Biosciences for about $12 billion

(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash. Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday. Under the terms of agreement, Avidity will separate its early-stage precision cardiology programs into a new company called Spinco. Novartis has been actively striking deals in 2025 as it looks to bolster its drug pipeline and drive future growth, and the Financial Times reported in August that the Swiss drugmaker had approached Avidity Biosciences for a potential takeover offer. (Reporting by Angela Christy in Bengaluru)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Indianews Syndication

Recent Posts

Nike aims to design half of its China sportswear products locally

By Danielle Kaye BEAVERTON, Oregon, Nov 17 (Reuters) - Nike is working toward designing and…

2 minutes ago

Waymo pauses robotaxi rides on US freeways after California ban

By Abhirup Roy SAN FRANCISCO, Nov 17 (Reuters) - Alphabet's Waymo has halted operations of…

3 minutes ago

UPDATE 2-NBA Results

Nov 18 (Stats Perform) - Results from the NBA games on Wednesday (home team in…

7 minutes ago

RUSSIA'S PUTIN, AT APEC CEO SUMMIT, SAYS US DOLLAR SHARE IN RUSSIAN TRADE HAS SHARPLY FALLEN

RUSSIA'S PUTIN, AT APEC CEO SUMMIT, SAYS US DOLLAR SHARE IN RUSSIAN TRADE HAS SHARPLY…

11 minutes ago

Tech outage wave reaches US government; Trump says all is 'fine'

By Raphael Satter, Trevor Hunnicutt, Nandita Bose and Bo Erickson WASHINGTON, Nov 17 (Reuters) -…

13 minutes ago

Tech outage wave reaches US government; Trump says all is 'fine'

By Raphael Satter, Trevor Hunnicutt, Nandita Bose and Bo Erickson WASHINGTON, Nov 17 (Reuters) -…

14 minutes ago